Anterograde amnesia

Summary

Anterograde amnesia (MONDO:0003398) is a disease and 1 clinical trial. Top therapeutic interventions include midazolam and remimazolam besylate. A subtype of amnestic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anterograde amnesia
Mondo ID	MONDO:0003398
MeSH	D020324
DOID	DOID:5340
ICD-10-CM	R41.1
ICD-11	661071789
UMLS	C0233795
MedGen	115938
Is cancer (heuristic)	no

Disease family

This is a subtype of amnestic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › amnestic disorder › anterograde amnesia

Related subtypes (3): transient global amnesia, retrograde amnesia, alcohol amnestic disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05350085	Not specified	UNKNOWN	Remimazolam in the Extraction of Impacted Wisdom Teeth

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MIDAZOLAM	4	1
REMIMAZOLAM BESYLATE	4	1